Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

When is Post-Operative Bleeding Most Likely to Occur after a Tonsillectomy?
Discussion Tonsillectomy is one of the most commonly performed surgical procedures in the US with pressure equalizing tubes and circumcisions also being among the top procedures. About 500,000 are performed yearly in the US in children under 15 years. Primary indications are recurrent throat infections (e.g. “
Source: PediatricEducation.org - July 19, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, Pa., July 12, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Co... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, DARZALEX FASPRO®, daratumumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2021 Category: Pharmaceuticals Source Type: news

FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 12, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Hemady (dexamethasone)
Title: Hemady (dexamethasone)Category: MedicationsCreated: 6/29/2021 12:00:00 AMLast Editorial Review: 6/29/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 29, 2021 Category: Cancer & Oncology Source Type: news

Uganda: Pharmacists Warn Against Dexamethasone Use As Covid Drug
[Monitor] Pharmacists have asked doctors to stop prescribing dexamethasone for Covid-19 patients undergoing home-based care, saying the medicine lowers immunity and increases the risk of developing severe disease. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 24, 2021 Category: African Health Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

New study may help explain low oxygen levels in COVID-19 patients
A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment for those with the virus. (Source: World Pharma News)
Source: World Pharma News - June 2, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New study may help explain low oxygen levels in COVID-19 patients
(University of Alberta Faculty of Medicine& Dentistry) A new study by University of Alberta researchers sheds light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 2, 2021 Category: Infectious Diseases Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Lies Beneath: The Sorcerer's Apprentice and Dexamethasone
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - June 1, 2021 Category: Emergency Medicine Tags: What Lies Beneath Source Type: news

Selinexor, bortezomib, dexamethasone cost effective in previously treated multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Cortisol Secretion, Mortality Link Explored in Adrenal Incidentalomas
WEDNESDAY, May 26, 2021 -- For patients with adrenal incidentalomas, autonomous cortisol secretion is associated with mortality at a plasma cortisol level after a 1-mg dexamethasone suppression test (cortisolDST) of 83 nmol/L or higher, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2021 Category: Pharmaceuticals Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mild Cortisol Excess Increases Mortality in Adrenal Incidentaloma Mild Cortisol Excess Increases Mortality in Adrenal Incidentaloma
Autonomous cortisol secretion level following dexamethasone suppression test in patients with adrenal incidentalomas but without Cushing syndrome found to have prognostic value.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 24, 2021 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

DDMA asks pharmacies to display available stock, cost of COVID-19 drugs prominently
The drugs are Ivermectin tablets, Doxycyclin tablets/capsule, Methyl Prednisolone tablets and injections, Dexamethasone tablets and injections, Budosenide Inhalers and Respules Favipiravir tablets, Apixaban tablets and Enoxaparin Sodium/ Clexane, it said. (Source: The Economic Times)
Source: The Economic Times - May 22, 2021 Category: Consumer Health News Source Type: news

Maxidex (dexamethasone) Suspension
Title: Maxidex (dexamethasone) SuspensionCategory: MedicationsCreated: 5/21/2021 12:00:00 AMLast Editorial Review: 5/21/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 21, 2021 Category: Drugs & Pharmacology Source Type: news

Maxitrol (neomycin and polymyxin B sulfates and dexamethasone)
Title: Maxitrol (neomycin and polymyxin B sulfates and dexamethasone)Category: MedicationsCreated: 5/21/2021 12:00:00 AMLast Editorial Review: 5/21/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - May 21, 2021 Category: Opthalmology Source Type: news

Preoperative DEX and Cognitive Function After Cardiac Surgery Preoperative DEX and Cognitive Function After Cardiac Surgery
Might prophylactic administration of dexamethasone reduce the risk of postoperative cognitive decline?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2021 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Dexamethasone Does Not Increase Risk for Surgical-Site Infection
FRIDAY, May 7, 2021 -- For adults undergoing nonurgent, noncardiac surgery, dexamethasone is noninferior to placebo with respect to surgical-site infection within 30 days, according to a study published in the May 6 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2021 Category: Pharmaceuticals Source Type: news

Dexamethasone for Nausea Does Not Raise Risk of Surgical-Site Infections Dexamethasone for Nausea Does Not Raise Risk of Surgical-Site Infections
Fears that dexamethasone may increase the risk of surgical-site infection when given to prevent nausea and vomiting after an operation appear to be unfounded.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 6, 2021 Category: Surgery Tags: General Surgery News Source Type: news

FDA D.I.S.C.O. Burst: Approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four lines of prior therapy
Listen to a soundcast of the February 26, 2021 FDA approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adults patients with refractory multiple myeloma who received at least four prior lines of therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Steroids Can Be Stopped in Some Older Myeloma Patients Steroids Can Be Stopped in Some Older Myeloma Patients
In intermediate-fit elderly patients newly diagnosed with multiple myeloma, dexamethasone can be stopped during maintenance without having an adverse effect on outcome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression - free, three - year overall survival similar for lenalidomide maintenance regimen without dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
WEDNESDAY, March 24, 2021 -- Dose/schedule-adjusted lenalidomide-dexamethasone (Rd) followed by a maintenance regimen of lenalidomide 10 mg/day without dexamethasone (Rd-R) is feasible for older patients with multiple myeloma (MM), with survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2021 Category: Pharmaceuticals Source Type: news

New figures show dexamethasone treatment for COVID-19 has so far saved 22,000 lives in UK, NHS England (published 23rd March 2021)
These figures were released by NHS England, who noted dexamethasone has also saved ~1 million lives worldwide since the positive findings from RECOVERY trial of decreased risk of death by a third in patients on ventilators and by almost a fifth in those on oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 24, 2021 Category: Consumer Health News Source Type: news

COVID treatment developed in the NHS saves a million lives
Dexamethasone, an inexpensive and widely available steroid, has saved around one million lives worldwide since its discovery as an effective treatment for COVID-19 in a clinical trial in the NHS. (Source: NHS Networks)
Source: NHS Networks - March 23, 2021 Category: UK Health Source Type: news

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both month...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a sta...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

DEX Blunts Postspinal Hypotension in Geriatric Patients DEX Blunts Postspinal Hypotension in Geriatric Patients
Might dexamethasone be effective in in preventing or decreasing the incidence of post-spinal anesthesia hypotension in elderly patients?BMC Anesthesiology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 24, 2021 Category: Orthopaedics Tags: Anesthesiology Journal Article Source Type: news

UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC
NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news

COVID-19 Pandemic has Shown Humanity at its Best – & at its Worst
A health worker at a local health centre in Kinshasa, Democratic Republic of the Congo, prepares a vaccine injection. The dispatch of millions of COVID-19 vaccines to Africa started in February. Credit: UNICEF/Sibylle DesjardinsBy Tedros Adhanom GhebreyesusGENEVA, Feb 11 2021 (IPS) WHO and UNICEF have a long, deep and very special relationship. Neither of us could do what we do without the other. UNICEF’s success is WHO’s success, and we are proud to be your partner on so many issues: Ebola, polio, maternal health, nutrition, infection prevention and control, primary health care – the list is long. Neve...
Source: IPS Inter Press Service - Health - February 11, 2021 Category: International Medicine & Public Health Authors: Tedros Adhanom Ghebreyesus Tags: Development & Aid Education Global Globalisation Headlines Health Inequity Poverty & SDGs TerraViva United Nations Source Type: news

Oral Mosapride as Anti-emetic Following General Anesthesia Oral Mosapride as Anti-emetic Following General Anesthesia
Might the addition of prophylactic oral mosapride to a protocol including dexamethasone and ondansetron further reduce postoperative nausea and vomiting after general anesthesia?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 2, 2021 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news

Dexamethasone Harmful in Chronic Subdural Hematoma Dexamethasone Harmful in Chronic Subdural Hematoma
The steroid, which is commonly used as a treatment for chronic subdural hematoma, appears to be doing more harm than good in this indication, a new randomized trial has shown.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 7, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Dexamethasone Not Favored for Chronic Subdural Hematoma
Dexamethasone worse than placebo with respect to favorable outcome at six months (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 30, 2020 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Dexamethasone Not Favored for Chronic Subdural Hematoma
WEDNESDAY, Dec. 30, 2020 -- Dexamethasone results in fewer favorable outcomes than placebo among patients with symptomatic chronic subdural hematoma, according to a study published online Dec. 16 in the New England Journal of Medicine. Peter J.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2020 Category: Pharmaceuticals Source Type: news

The breakthrough medicines that could change the course of Covid
Dexamethasone demonstrates power of large-scale, randomised trials in finding effective medicinesCoronavirus – latest updatesSee all our coronavirus coverageIt remains one of the most dramatically successful outcomes in the battle against Covid-19. A cheap treatment for inflammation was found to save lives of seriously ill patients while a trio of much-touted therapies were shown to have no effect.It is now estimated that the discovery of the effectiveness of the drug dexamethasone has saved around 650,000 lives across the world, according to Professor Martin Landray, a founder of the Recovery programme – the w...
Source: Guardian Unlimited Science - December 27, 2020 Category: Science Authors: Robin McKie Observer Science Editor Tags: Coronavirus Medical research Biology UK news Infectious diseases Health World news Science Society Source Type: news

Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma
Investigators found that baseline dexamethasone use was associated with poor overall survival (OS) in glioblastoma patients receiving anti –PD-1 or anti–PD-L1 therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Bill Gates Thinks About the State of the Fight Against COVID-19
Bill Gates isn’t about to be contemplating his touchdown dance yet. You don’t get to devote your life to battling the world’s most intractable problems by declaring victory before a fight is over. But in a letter Gates released this morning, headlined, “These breakthroughs will make 2021 better than 2020,” it’s clear that the co-director of the Bill and Melinda Gates Foundation is feeling pretty sanguine about the year ahead—particularly when it comes to COVID-19. The Gates letter, which comes a month before the expected January release of Melinda Gates’s Annual Letter, sees ...
Source: TIME: Health - December 22, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

Covid Guide: How to Get Through the Pandemic
Times are tough now, but the end is in sight. If we hunker down, keep our families safe during the holidays and monitor our health at home, life will get better in the spring. Here ’s how to get through it. (Source: NYT Health)
Source: NYT Health - December 19, 2020 Category: Consumer Health News Authors: Tara Parker-Pope Tags: Coronavirus Risks and Safety Concerns Disease Rates Chronic Condition (Health) Coronavirus (2019-nCoV) Dexamethasone (Drug) Telemedicine Vaccination and Immunization Travel Warnings Tests (Medical) Protective Clothing and Gear Winter ( Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news